Yet, with the exception of a phase-I trial with CAR-T cells in neuroblastoma patients ([133], see also Section 5), to date no L1CAM-based treatments have reached clinical use, although there are biotech companies that are actively pursuing this goal. This evidence concerns the gene L1CAM and neuroblastoma.